1. Home
  2. ICMB vs RNTX Comparison

ICMB vs RNTX Comparison

Compare ICMB & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Investcorp Credit Management BDC Inc.

ICMB

Investcorp Credit Management BDC Inc.

HOLD

Current Price

$2.82

Market Cap

40.8M

Sector

Finance

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

BUY

Current Price

$1.53

Market Cap

38.9M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
ICMB
RNTX
Founded
2012
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.8M
38.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ICMB
RNTX
Price
$2.82
$1.53
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
42.3K
234.4K
Earning Date
11-12-2025
11-14-2025
Dividend Yield
18.70%
N/A
EPS Growth
31.51
N/A
EPS
0.38
N/A
Revenue
$17,931,778.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$4.75
N/A
P/E Ratio
$7.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.46
$1.04
52 Week High
$3.47
$3.50

Technical Indicators

Market Signals
Indicator
ICMB
RNTX
Relative Strength Index (RSI) 47.40 58.01
Support Level $2.74 $1.34
Resistance Level $2.90 $1.58
Average True Range (ATR) 0.09 0.10
MACD -0.01 0.01
Stochastic Oscillator 21.87 87.50

Price Performance

Historical Comparison
ICMB
RNTX

About ICMB Investcorp Credit Management BDC Inc.

Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: